MUC5B promoter variant and survival in rheumatoid arthritis-associated interstitial lung disease

Klein, J; Wheeler, AM; Baker, JF; Yang, Y; Roul, P; Frideres, H; Wysham, KD; Kerr, GS; Reimold, A; Ascherman, DP; Kunkel, GA; Cannon, GW; Monach, PA; Poole, JA; Thiele, GM; Mikuls, TR; England, BR

doi:10.1093/rheumatology/keae615

MUC5B promoter variant and survival in rheumatoid arthritis-associated interstitial lung disease

Rheumatology (Oxford)Published 6 Nov 2024Cohort study

Main finding · All-cause mortality by MUC5B rs35705950 promoter variant statusResultAdjusted hazard ratio (mortality) 0.97 95% CI 0.68–1.37

Read the original article ↗PubMed

Cite

Authors' conclusion

While associated with RA-ILD risk, the MUC5B promoter variant was not predictive of survival among RA-ILD patients in this multicentre cohort.

Study context

Population: Participants in the Veteran Affairs Rheumatoid Arthritis (VARA) registry with validated ILD diagnoses (RA-associated interstitial lung disease (RA-ILD)); mean age 69 years, 95% male, 73% White, 85% smoking historyvariant in 33.5%
Participants: 263 participants

Exposure: MUC5B rs35705950 promoter variant present vs absent
Outcome: Survival (mortality)

Methodological detailsmulticentre, registry-based, Cox regression adjusted for potential confounders, autosomal dominant inheritance assumed, Survival and cause of death from VA death records and the National Death Index

Multicentre
Registry-based
Cox regression adjusted for potential confounders
Autosomal dominant inheritance assumed
Survival and cause of death from VA death records and the National Death Index

Main finding

As reported in the abstract

All-cause mortality by MUC5B rs35705950 promoter variant status

Adjusted hazard ratio (mortality)

0.97

95% CI 0.68–1.37

By group

MUC5B variant12.2mortality rate · 95% CI 9.4–15.8 · /100 PY

No variant11.1mortality rate · 95% CI 9.1–13.5 · /100 PY

MUC5B rs35705950 promoter variant presentvs absent

aHR (mortality) 0.97 (95% CI 0.68–1.37)

Observational data: associations, not effects.

Further findings

Mortality, clinical usual interstitial pneumonia (UIP) pattern (stratified by ILD pattern)

	← Lower risk ←→ Higher risk →	aHR (mortality) (95% CI)
MUC5B status	0.512	0.86 (0.55–1.35)
	0.512Adjusted hazard ratio (mortality) (log scale)

Mortality, clinical non-UIP pattern (stratified by ILD pattern)

	← Lower risk ←→ Higher risk →	aHR (mortality) (95% CI)
MUC5B status	0.512	1.15 (0.63–2.09)
	0.512Adjusted hazard ratio (mortality) (log scale)

Respiratory-related death

	← Lower risk ←→ Higher risk →	aHR (95% CI)
MUC5B statusNot significantly associated	0.512	0.83 (0.42–1.66)
	0.512Adjusted hazard ratio (log scale)

Non-respiratory causes of death

	← Lower risk ←→ Higher risk →	aHR (95% CI)
MUC5B statusNot significantly associated	0.512	1.08 (0.72–1.62)
	0.512Adjusted hazard ratio (log scale)

Original publication

MUC5B promoter variant and survival in rheumatoid arthritis-associated interstitial lung disease. Rheumatology (Oxford). Published 6 November 2024. doi:10.1093/rheumatology/keae615

Read the original article ↗

Composed by AI from the published abstract and checked against it. How Briefs are made →